IDRA 21

• Description :

  IDRA 21 is a positive and orally active modulator of the AMPA receptor. IDRA 21 facilitates excitatory neurotransmission via GluR1/2 receptors. IDRA 21 has the potential for the research of cognitive/memory disorders, including those associated with aging[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  IGluR

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/idra-21.html

• Purity :

  99.66

• Solubility :

  DMSO : 250 mg/mL (ultrasonic)

• Smiles :

  CC(NC1=CC=C(Cl)C=C12)NS2(=O)=O

• Molecular Formula :

  C8H9ClN2O2S

• Molecular Weight :

  232.69

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Buccafusco JJ, et al. The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys. Neuropharmacology. 2004 Jan;46 (1) :10-22. doi: 10.1016/j.neuropharm.2003.07.002.|[2]Yamada KA, et al. The diazoxide derivative IDRA 21 enhances ischemic hippocampal neuron injury. Ann Neurol. 1998 May;43 (5) :664-9.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  AMPA Receptor

• CAS Number :

  [22503-72-6]